Biotronik has announced CE approval and the first implantations of the Sentus ProMRI lead. Biotronik’s bipolar cardiac resynchronisation therapy lead is the first MR conditional lead with a 4 french diameter-approximately 1.6 millimetres. An ultra-thin lead, it enables access to particularly challenging vessels and offers expanded pacing options. In addition to these important therapeutic benefits, the Sentus leads are unique in that they allow patients to undergo MRI (magnetic resonance imaging) scans. The new cardiac resynchronisation therapy lead received European market (CE mark) approval in early February, a press release reports.
Philippe Ritter, Bordeaux University Hospital, France, comments, “Heart failure patients require complex disease management. Particularly as patients age and develop comorbidities, they may need an MRI scan-the gold standard for soft tissue imaging. BIOTRONIK ProMRI leads and implantable devices allow me to offer my heart failure patients reliable therapy, enhancing their quality of life.”
“With Biotronik Home Monitoring, I can continuously monitor a therapy’s effectiveness and react quickly if the patient’s condition changes or deteriorates,” says Christof Kolb, German Heart Centre, Munich, Germany. “This is particularly important for heart failure patients, as their status can change quickly and often.”